EUVIMEDEUVIMED entdecken
Crossref

Combination of S-1 and the oral ATR inhibitor ceralasertib is effective against pancreatic cancer cells

Yoshihito Morimoto, Kimihiko Takada, Ami Nakano, Osamu Takeuchi, Kazuhiro Watanabe, Masayoshi Hirohara, Yutaka Masuda

Cancer Chemotherapy and Pharmacology · 2024-12 · 94 (6) · 763-774

DOI: 10.1007/s00280-024-04716-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, online erschienen am 14.09.2024. Verfasst von Yoshihito Morimoto und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Education and Research on Clinical Pharmacy, Showa Pharmaceutical University, 3-3165 Higashi-Tamagawagakuen, Machida, Tokyo, 194-8543, Jap…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Apoptosis, Cell Proliferation, Xenograft Model Antitumor Assays. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsApoptosisCell ProliferationXenograft Model Antitumor AssaysPyrimidinesOxonic AcidDrug CombinationsTegafurDrug SynergismPyrazinesHumansAnimalsCell Line, TumorMiceAntineoplastic Combined Chemotherapy ProtocolsMice, NudeAtaxia Telangiectasia Mutated ProteinsCheckpoint Kinase 1Protein Kinase InhibitorsMice, Inbred BALB CFemalePyrazolesIndolesMorpholinesSulfonamides

Stichwörter der Autor:innen

ATRCeralasertibChk1Pancreatic cancerS-1

Substanzen

PyrimidinesOxonic AcidDrug CombinationsS 1 (combination)TegafurceralasertibPyrazinesATR protein, humanAtaxia Telangiectasia Mutated ProteinsCheckpoint Kinase 1

Autor:innen und Institutionen

  • Center for Education and Research on Clinical Pharmacy, Showa Pharmaceutical University, 3-3165 Higashi-Tamagawagakuen, Machida, Tokyo, 194-8543, Japan. y-morimoto@ac.shoyaku.ac.jp.
  • Center for Education and Research on Clinical Pharmacy, Showa Pharmaceutical University, 3-3165 Higashi-Tamagawagakuen, Machida, Tokyo, 194-8543, Japan.
  • BioMedical Laboratory, Department of Research, Kitasato Institute Hospital, Tokyo, 108-8642, Japan.

Zitieren

APA

Morimoto, Y., Takada, K., Nakano, A., Takeuchi, O., Watanabe, K., Hirohara, M., & Masuda, Y. (2024). Combination of S-1 and the oral ATR inhibitor ceralasertib is effective against pancreatic cancer cells. Cancer Chemotherapy and Pharmacology, 94(6), 763-774. https://doi.org/10.1007/s00280-024-04716-x

Vancouver

Morimoto Y, Takada K, Nakano A, Takeuchi O, Watanabe K, Hirohara M, et al. Combination of S-1 and the oral ATR inhibitor ceralasertib is effective against pancreatic cancer cells. Cancer Chemotherapy and Pharmacology. 2024;94(6):763-774. doi:10.1007/s00280-024-04716-x

BibTeX
@article{Morimoto2024,
  author = {Morimoto, Yoshihito and Takada, Kimihiko and Nakano, Ami and Takeuchi, Osamu and Watanabe, Kazuhiro and Hirohara, Masayoshi and Masuda, Yutaka},
  title = {Combination of S-1 and the oral ATR inhibitor ceralasertib is effective against pancreatic cancer cells},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2024},
  volume = {94},
  number = {6},
  pages = {763--774},
  doi = {10.1007/s00280-024-04716-x}
}
Kostenlos starten →